Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

House dust mite allergy immunotherapy - ALK-Abello

Drug Profile

House dust mite allergy immunotherapy - ALK-Abello

Alternative Names: ACARIZAX; ALK HDM; ALK Mite Tablet; HDM AIT; HDM SLIT drops - ALK-Abello; HDM SLIT extract - ALK-Abello; HDM SLIT tablet- ALK-Abello; House dust mite extract - ALK-Abello; House dust mite SLIT drops - ALK-Abello; House dust mite SLIT One Dermatophagoides mixture - ALK-Abello; House dust mite SLIT tablet - ALK-Abello; MITICURE; Mitizax; MK-8237; Odactra; SCH-900237; SLITONEULTRA-HDM; SQ®HDM SLIT-tablet - ALK-Abello; TO-203

Latest Information Update: 08 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALK-Abello
  • Developer Abbott Laboratories; ALK-Abello; Merck & Co; Seqirus; Torii Pharmaceutical
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
  • Phase III Atopic dermatitis

Most Recent Events

  • 20 Jun 2019 ALK-Abello plans a phase III trial in Allergic rhinitis (In children, Treatment-experienced) in Germany and France (Sublingual) (NCT04145219) (EudraCT2019-000560-22)
  • 24 Jun 2018 Biomarkers information updated
  • 21 Feb 2018 Launched for Allergic asthma in France (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top